MARKET WIRE NEWS

Tracking Baker Brothers Portfolio - Q2 2025 Update

Source: SeekingAlpha

2025-09-15 20:21:09 ET

This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F stock portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 08/14/2025. The 13F portfolio value increased from $9.36B to $10.31B. Although there are ~100 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. There are 26 positions that are significantly large (more than 0.5% of the portfolio each), and they are the focus of this article. The five largest stakes are BeOne Medicines, Incyte, ACADIA Pharma, Insmed, and Summit Therapeutics. They add up to ~65% of the portfolio. Please visit our Tracking Baker Brothers Portfolio series to get an idea of their investment philosophy and our previous update for the fund’s moves during Q1 2025....

Read the full article on Seeking Alpha

For further details see:

Tracking Baker Brothers Portfolio - Q2 2025 Update
BeiGene

NASDAQ: BEIGF

BEIGF Trading

0.0% G/L:

$23.75 Last:

100 Volume:

$23.75 Open:

mwn-app Ad 300

BEIGF Latest News

BEIGF Stock Data

$38,603,023,416
747,457,849
N/A
299
N/A
Biotechnology & Life Sciences
Healthcare
CH
Basel

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App